Bhatia Sangeeta N. 4

4 · VERTEX PHARMACEUTICALS INC / MA · Filed Feb 18, 2026

Research Summary

AI-generated summary of this filing

Updated

Vertex (VRTX) Director Sangeeta Bhatia Sells 266 Shares

What Happened

  • Sangeeta N. Bhatia, a director of Vertex Pharmaceuticals (VRTX), sold 266 shares on 2026-02-13 at $500.00 per share, for total proceeds of $133,000. The sale is recorded as an open-market/private sale (code S).

Key Details

  • Transaction date: 2026-02-13; Price: $500.00 per share; Total value: $133,000.
  • Shares owned after transaction: Not disclosed in this Form 4.
  • Footnote: The sale was made pursuant to a company-approved Rule 10b5-1 trading plan entered into on 2025-05-27.
  • Filing: Form 4 was filed on 2026-02-18 (within the required two business days following the transaction, given the Presidents’ Day holiday), so the filing appears timely.

Context

  • A 10b5-1 plan indicates the sale was pre-arranged according to a set plan, which is commonly used by insiders to sell shares without contemporaneous trading decisions. Sales are routine insider activity and do not necessarily indicate a change in company outlook; retail investors often view purchases as stronger signals of insider confidence.

Insider Transaction Report

Form 4
Period: 2026-02-13
Transactions
  • Sale

    Common Stock

    [F1]
    2026-02-13$500.00/sh266$133,0004,299 total
Footnotes (1)
  • [F1]Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/27/2025.
Signature
/s/ Christiana Stevenson, Attorney-in-Fact|2026-02-18

Documents

1 file
  • 4
    wk-form4_1771449836.xmlPrimary

    FORM 4